These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

658 related items for PubMed ID: 8807097

  • 1. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma.
    Demirer T, Buckner CD, Gooley T, Appelbaum FR, Rowley S, Chauncey T, Lilleby K, Storb R, Bensinger WI.
    Bone Marrow Transplant; 1996 Jun; 17(6):937-41. PubMed ID: 8807097
    [Abstract] [Full Text] [Related]

  • 2. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone.
    Alegre A, Tomás JF, Martínez-Chamorro C, Gil-Fernández JJ, Fernández-Villalta MJ, Arranz R, Díaz MA, Granda A, Bernardo MR, Escudero A, López-Lorenzo JL, Fernández-Rañada JM.
    Bone Marrow Transplant; 1997 Aug; 20(3):211-7. PubMed ID: 9257889
    [Abstract] [Full Text] [Related]

  • 3. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M, Burns LJ, Barker JN, Miller JS, Defor TE, Olujohungbe AB, Weisdorf DJ.
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [Abstract] [Full Text] [Related]

  • 4. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
    Alexander ET, Towery JA, Miller AN, Kramer C, Hogan KR, Squires JE, Stuart RK, Costa LJ.
    Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
    [Abstract] [Full Text] [Related]

  • 5. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
    Hohaus S, Martin H, Wassmann B, Egerer G, Haus U, Färber L, Burger KJ, Goldschmidt H, Hoelzer D, Haas R.
    Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688
    [Abstract] [Full Text] [Related]

  • 6. Effect of different chemotherapy regimens on peripheral-blood stem-cell collections in patients with breast cancer receiving granulocyte colony-stimulating factor.
    Demirer T, Buckner CD, Storer B, Lilleby K, Rowley S, Clift R, Appelbaum FR, Storb R, Bensinger WI.
    J Clin Oncol; 1997 Feb; 15(2):684-90. PubMed ID: 9053494
    [Abstract] [Full Text] [Related]

  • 7. Collection of peripheral blood progenitor cells for autografting with low-dose cyclophosphamide plus granulocyte colony-stimulating factor.
    Bellido M, Sureda A, Martino R, Madoz P, García J, Brunet S.
    Haematologica; 1998 May; 83(5):428-31. PubMed ID: 9658727
    [Abstract] [Full Text] [Related]

  • 8. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
    Lemoli RM, Cavo M, Fortuna A.
    J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
    [Abstract] [Full Text] [Related]

  • 9. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF.
    Koç ON, Gerson SL, Cooper BW, Laughlin M, Meyerson H, Kutteh L, Fox RM, Szekely EM, Tainer N, Lazarus HM.
    J Clin Oncol; 2000 May; 18(9):1824-30. PubMed ID: 10784622
    [Abstract] [Full Text] [Related]

  • 10. Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor.
    Schwartzberg LS, Birch R, Hazelton B, Tauer KW, Lee P, Altemose R, George C, Blanco R, Wittlin F, Cohen J.
    J Hematother; 1992 May; 1(4):317-27. PubMed ID: 1285381
    [Abstract] [Full Text] [Related]

  • 11. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
    Weaver CH, Schulman KA, Buckner CD.
    Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
    [Abstract] [Full Text] [Related]

  • 12. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies.
    Hamadani M, Kochuparambil ST, Osman S, Cumpston A, Leadmon S, Bunner P, Watkins K, Morrison D, Speir E, Deremer D, Kota V, Jillella A, Craig M, Awan F.
    Biol Blood Marrow Transplant; 2012 Jul; 18(7):1128-35. PubMed ID: 22248715
    [Abstract] [Full Text] [Related]

  • 13. Peripheral-blood stem-cell collections after paclitaxel, cyclophosphamide, and recombinant human granulocyte colony-stimulating factor in patients with breast and ovarian cancer.
    Demirer T, Rowley S, Buckner CD, Appelbaum FR, Lilleby K, Storb R, Schiffman K, Bensinger WI.
    J Clin Oncol; 1995 Jul; 13(7):1714-9. PubMed ID: 7541450
    [Abstract] [Full Text] [Related]

  • 14. Factors that influence collection and engraftment of autologous peripheral-blood stem cells.
    Bensinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K, Gooley T, Demirer T, Schiffman K, Weaver C.
    J Clin Oncol; 1995 Oct; 13(10):2547-55. PubMed ID: 7595706
    [Abstract] [Full Text] [Related]

  • 15. A randomized trial of two doses of cyclophosphamide with etoposide and G-CSF for mobilization of peripheral blood stem cells in 318 patients with stage II-III breast cancer.
    Schwartzberg LS, Weaver CH, Birch R, Manner C, Tauer K, Beeker T, Morgan-Ihrig C, MacAneny B, Leff R, Smith R, Hainsworth J, Greco T, Schwerkoske J, Murphy MN, Buckner CD.
    J Hematother; 1998 Apr; 7(2):141-50. PubMed ID: 9597571
    [Abstract] [Full Text] [Related]

  • 16. Collection of peripheral blood stem cells following administration of paclitaxel, cyclophosphamide, and filgrastim in patients with breast and ovarian cancer.
    Weaver CH, Schwartzberg LS, Birch R, Greco FA, Hainsworth J, Drapkin R, Campos L, Grapski R, Schwerkoske J, Lautersztain J, Hazelton B, Schnell F, Babcock W, Buckner CD.
    Biol Blood Marrow Transplant; 1997 Jun; 3(2):83-90. PubMed ID: 9267668
    [Abstract] [Full Text] [Related]

  • 17. Peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequential GM-CSF/G-CSF in non-Hodgkin's lymphoma patients: a randomized prospective study.
    Gazitt Y, Callander N, Freytes CO, Shaughnessy P, Liu Q, Tsai TW, Devore P.
    J Hematother Stem Cell Res; 2000 Oct; 9(5):737-48. PubMed ID: 11091498
    [Abstract] [Full Text] [Related]

  • 18. Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma.
    Hiwase DK, Bollard G, Hiwase S, Bailey M, Muirhead J, Schwarer AP.
    Cytotherapy; 2007 Oct; 9(6):539-47. PubMed ID: 17882718
    [Abstract] [Full Text] [Related]

  • 19. Second attempts at mobilization of peripheral blood stem cells in patients with initial low CD34+ cell yields.
    Weaver CH, Tauer K, Zhen B, Schwartzberg LS, Hazelton B, Weaver Z, Lewkow L, Allen C, Longin K, Buckner CD.
    J Hematother; 1998 Jun; 7(3):241-9. PubMed ID: 9621257
    [Abstract] [Full Text] [Related]

  • 20. No polarization of type 1 or type 2 precursor dendritic cells in peripheral blood stem cell collections of non-hodgkin's lymphoma patients mobilized with cyclophosphamide plus G-CSF, GM-CSF, or GM-CSF followed by G-CSF.
    Gazitt Y, Akay C, Thomas C.
    Stem Cells Dev; 2006 Apr; 15(2):269-77. PubMed ID: 16646673
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.